Dual Studies Reveal Early Successes for mRNA HIV Vaccine Strategies

INTERVIEW: High hopes for new HIV vaccine

Researchers from the Fred Hutchinson Cancer Center in Seattle have tested a new HIV vaccine using mRNA, the technology behind many COVID-19 vaccines. Scientists say results from the early-stage clinical trial offer hope for significant progress in the global effort to develop a safe and effective HIV vaccine. For this episode of Weekend One on One, Angelica Waite has been speaking with Associate Professor Seth Cheetham, Deputy Director of BASE m…

Dual studies reveal early successes for mRNA HIV vaccine strategies

HIV vaccine efforts have been slowed by the difficulty of getting neutralizing antibodies to target the correct locations of the diverse variants of HIV. Neutralizing antibodies are proteins produced by the immune system that bind to and block the activity of viruses, bacteria, or other pathogens.

Breakthrough in HIV Vaccine Development: mRNA Technology Shows Promise in Eliciting Neutralizing Antibodies - Scientific Inquirer

Researchers demonstrate that membrane-anchored HIV vaccines delivered via mRNA platform can trigger potent immune responses, offering new hope for one of medicine’s most elusive goals After more than four decades since the first reported cases of AIDS, the quest for an effective HIV vaccine has taken a significant step forward. A groundbreaking study published in Science Translational Medicine reveals that mRNA technology—the same platform that …